NCT05841563 - Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

April 30, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

PM54

"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"

Trial Locations (3)

1070

RECRUITING

Institut Jules Bordet, Anderlecht

28050

RECRUITING

HM Universitario Sanchinarro, Madrid

78229-3307

RECRUITING

South Texas Accelerated Research Therapeutics, San Antonio